Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated
This study evaluates the use of chemotherapy with cabazitaxel in addition to abiraterone
acetate, prednisone, and leuprolide in neoadjuvant setting prior to radical prostatectomy in
patients with high-risk prostate carcinoma. Half of the participants will receive treatment
with abiraterone acetate, prednisone, leuprolide, and cabazitaxel, while the other half will
receive only abiraterone acetate, prednisone, and leuprolide.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society